ATR 1072 in Participants With PRKAG2 Syndrome
Trial statusNot yet recruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age18-65
SponsorAtrium Therapeutics
About this trial
ATR 1072 is an investigational medicine being studied in adults with PRKAG2 Syndrome. This study will evaluate the safety of ATR 1072 and how the body processes the drug. Researchers will also assess how ATR 1072 affects PRKAG2 activity and measures of heart disease.
Eligibility criteria
Qualifiers
Adults 18 to 65 years of age.
Pathogenic, likely pathogenic, or variant of uncertain significance (VUS) in PRKAG2 confirmed by genetic testing.
Clinical manifestations consistent with PRKAG2 Syndrome.
Able and willing to comply with study procedures.
Disqualifiers
Pregnancy or breastfeeding.
Significant hepatic, renal, hematologic, or cardiovascular abnormalities that may increase study risk.
NYHA Class IV heart failure or left ventricular ejection fraction <45%.
Recent clinically significant cardiovascular events or procedures.
Trial design
Treatments tested in this trial
- ATR 1072
Treatment groups
37 Participants
are divided into 2 treatment groupsLocations
Sponsors and collaborators
Source ClinicalTrials.gov